Skip to main content
. 2021 Jul 22;125(9):1251–1260. doi: 10.1038/s41416-021-01488-6

Fig. 1. FGFR3-altered patients treated with ICB have similar clinical benefit.

Fig. 1

Patients with known FGFR3 status (n = 103) were classified as altered (n = 17) or wild-type (WT, n = 86) and compared for a OS (overall survival, Cox PH p = 0.38), b PFS (progression-free survival, Cox PH p = 0.95), and c Overall response rate. Response between FGFR3-altered and FGFR3 WT were compared by Responder (CR + PR) and Non-responder (SD + PD). Chi-square p = 0.73. d Interval estimates for coefficients in Cox PH model of OS for both univariate (black) and joint (blue) modelling. Variables significant at p < 0.05 marked with star. OS overall survival, CPH Cox-Proportional Hazards, PFS progression-free survival, WT wild type, TCC transitional cell carcinoma, LOT line of treatment, TMB tumour mutation burden, ECOG Eastern Cooperative Oncology Group, HR hazard ratio.